82 / 182
78 |
Integrated Report 2016
ANNUAL FINANCIAL STATEMENTS
(continued)
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
Attributable to holders of the parent
Issued
share
capital
Share
premium
Non-distributable
reserves
Retained
income
Total
attributable
to ordinary
share-
holders
Non-
controlling
interests
Total
Continuing
operations
Discontinued
operations
held-for-sale
Notes
R'000
R'000
R'000
R'000
R'000
R'000
R'000
R'000
As at 1 July 2014
16 878
510 920
426 415
1 784 688 2 738 901
118 578 2 857 479
Share issue
18, 19
10
2 018
2 028
2 028
Movement in share-based
payment reserve
20
16 098
16 098
16 098
Acquisition of non-controlling
interests in Ayrton Drug
Manufacturing Limited
1.2
(31)
(31)
(101)
(132)
Total comprehensive income
62 487
197 932
260 419
(330)
260 089
Profit for the year
197 932
197 932
877
198 809
Other comprehensive income
62 487
62 487
(1 207)
61 280
Disposal of non-controlling
interest in Bioswiss Proprietary
Limited
1.1
(14 101)
(14 101)
Dividends
9.1
(4 537)
(4 537)
Balance at 30 June 2015
16 888
512 938
505 000
1 982 589 3 017 415
99 509 3 116 924
Share issue
18, 19
1
189
190
190
Movement in share-based
payment reserve
20
12 578
12 578
12 578
Transfer to discontinued
operations
(58 200) 58 200
Implementation of BEE scheme
258
153 746
(44 587) 109 417
(79 883) 29 534
Acquisition of non-controlling
interests in Ayrton Drug
Manufacturing Limited
1.2
(1)
(1)
(1)
(2)
Total comprehensive income
24 137
86 798
168 801
279 736
12 614
292 350
Profit for the year
168 801
168 801
10 341
179 142
Other comprehensive income
24 137
86 798
110 935
2 273
113 208
Dividends
9.1
(190 762) (190 762)
(6 215) (196 977)
Balance at 30 June 2016
17 147
666 873
483 515
144 998 1 916 040 3 228 573
26 024 3 254 597